Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Galapagos NV is a clinical-stage biotechnology company focused on the discovery and development of innovative medicines, with a strategic emphasis on oncology and immunology. The company historically operated across small-molecule drug discovery and development, but since 2023 it has pivoted toward cell therapy–based oncology platforms following a broad strategic reset. Galapagos does not currently generate material recurring commercial revenue and primarily operates as a research and development organization.
The company was founded in 1999 by Onno van de Stolpe and built its early reputation in target discovery and small-molecule drug development, most notably through its long-standing collaboration with Gilead Sciences. Its lead product, filgotinib (Jyseleca), achieved approval in Europe and Japan for inflammatory diseases, but commercial rights and collaboration economics were later restructured. Beginning in 2022–2023, Galapagos redirected its capital and operations toward oncology, leveraging a strong balance sheet and divesting or discontinuing non-core programs.
Business Operations
Galapagos operates primarily through its Research & Development activities, with a focus on building a decentralized cell therapy platform for oncology. The company’s operations center on early- to mid-stage clinical development, translational research, and platform technology innovation rather than late-stage commercialization. Revenue generation is limited and primarily consists of legacy collaboration income, interest income, and milestone-related payments.
A central component of operations is Galapagos Oncology, which consolidates the company’s oncology strategy and assets. Key subsidiaries include CellPoint, which provides a decentralized manufacturing platform for cell therapies, and AboundBio, which contributes antibody discovery capabilities. Galapagos maintains no large-scale commercial manufacturing and relies on internal R&D teams and external partners for clinical execution and specialized capabilities.
Strategic Position & Investments
Galapagos’ strategic direction is centered on becoming a leader in next-generation, decentralized cell therapy for cancer, aiming to reduce manufacturing complexity and improve patient access. This strategy is supported by substantial investments made between 2022 and 2023, including the acquisitions of CellPoint and AboundBio, which together form the technological backbone of its oncology platform.
The company has also undertaken significant capital allocation actions, including returning excess cash to shareholders through tender offers while ring-fencing capital for oncology development. Galapagos has exited or deprioritized several legacy inflammation and fibrosis programs and no longer positions itself as a broad immunology pipeline company. Its investment focus is now tightly concentrated on oncology platforms, early clinical assets, and enabling technologies.
Geographic Footprint
Galapagos is headquartered in Belgium, with a significant operational presence in The Netherlands, which historically served as its corporate base. The company maintains research and development activities across Europe and the United States, reflecting the global nature of its clinical trials and technology platforms.
Through its subsidiaries and clinical programs, Galapagos has operational and investment exposure in North America and Western Europe, with past commercial reach into Japan via regional partnerships. While the company does not operate a global commercial infrastructure, its clinical and regulatory activities span multiple continents.
Leadership & Governance
Galapagos is led by an experienced executive team with deep backgrounds in pharmaceuticals, biotechnology, and capital allocation. The leadership philosophy emphasizes scientific innovation, disciplined investment, and strategic focus following the company’s recent transformation.
Key executives include:
- Paul Stoffels – Chief Executive Officer
- Henry Gosebruch – Chief Financial Officer
- Roger Pomerantz – Head of Oncology Cell Therapy
- Toon van Gerven – Chief Legal Officer
Founder Onno van de Stolpe previously served as long-term CEO and was instrumental in shaping Galapagos’ discovery-driven culture before stepping back from executive management. Data on certain governance roles and committee assignments is inconclusive based on available public sources.